Avecho Biotechnology has reported positive interim results from its phase III insomnia trial, raising the prospect of the company becoming the first to successfully register an over-the-counter CBD product in Australia, and internationally.
The firm said members of the Data Monitoring Board (DMB) – the only people permitted to see the early results – have recommended Avecho continue with its planned enrolment of a further 300 patients.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Eu lobortis elementum nibh tellus molestie nunc. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Magnis dis parturient montes nascetur ridiculus. Dui id ornare arcu odio ut sem. Nisl nunc mi ipsum faucibus vitae.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
A brilliant job by the CEO of Avecho, Dr Paul Gavin, to have achieved the positive results that he has from the interim analysis. After completing the trial, many people who have been struggling with insomnia for years/decades will be able to go to their pharmacy, purchase the medication, and find their lives changed for the better.